Suraksha Diagnostic IPO is a book built issue of Rs 846.25 crores. The issue is entirely an offer for sale of 1.92 crore shares.

Suraksha Diagnostic IPO opens for subscription on November 29, 2024 and closes on December 3, 2024. The allotment for the Suraksha Diagnostic IPO is expected to be finalized on Wednesday, December 4, 2024. Suraksha Diagnostic IPO will list on BSE, NSE with tentative listing date fixed as Friday, December 6, 2024.

Suraksha Diagnostic IPO price band is set at ₹420 to ₹441 per share. The minimum lot size for an application is 34 Shares. The minimum amount of investment required by retail investors is ₹14,994. The minimum lot size investment for sNII is 14 lots (476 shares), amounting to ₹209,916, and for bNII, it is 67 lots (2,278 shares), amounting to ₹1,004,598.

ICICI Securities LimitedNuvama Wealth Management Limited and SBI Capital Markets Limited are the book running lead managers of the Suraksha Diagnostic IPO, while Kfin Technologies Limited is the registrar for the issue.

Refer to Suraksha Diagnostic IPO RHP for detailed information.

Suraksha Diagnostic IPO Details

IPO Date November 29, 2024 to December 3, 2024
Listing Date [.]
Face Value ₹2 per share
Price Band ₹420 to ₹441 per share
Lot Size 34 Shares
Total Issue Size 19,189,330 shares
(aggregating up to ₹846.25 Cr)
Offer for Sale 19,189,330 shares of ₹2
(aggregating up to ₹846.25 Cr)
Issue Type Book Built Issue IPO
Listing At BSE, NSE
Share holding pre issue 52,080,758

Suraksha Diagnostic IPO Reservation

Investor Category Shares Offered
QIB Shares Offered Not more than 50% of the Net Offer
Retail Shares Offered Not less than 35% of the Net Offer
NII (HNI) Shares Offered Not less than 15% of the Net Offer

Suraksha Diagnostic IPO Anchor Investors Details

Suraksha Diagnostic IPO raises Rs 253.87 crore from anchor investors. Suraksha Diagnostic IPO Anchor bid date is November 28, 2024. Suraksha Diagnostic IPO Anchor Investors list

Bid Date November 28, 2024
Shares Offered 5,756,797
Anchor Portion Size (In Cr.) 253.87
Anchor lock-in period end date for 50% shares (30 Days) January 3, 2025
Anchor lock-in period end date for remaining shares (90 Days) March 4, 2025

Suraksha Diagnostic IPO Timeline (Tentative Schedule)

Suraksha Diagnostic IPO opens on November 29, 2024, and closes on December 3, 2024.

IPO Open Date Friday, November 29, 2024
IPO Close Date Tuesday, December 3, 2024
Basis of Allotment Wednesday, December 4, 2024
Initiation of Refunds Thursday, December 5, 2024
Credit of Shares to Demat Thursday, December 5, 2024
Listing Date Friday, December 6, 2024
Cut-off time for UPI mandate confirmation 5 PM on December 3, 2024

Suraksha Diagnostic IPO Lot Size

Investors can bid for a minimum of 34 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (Min) 1 34 ₹14,994
Retail (Max) 13 442 ₹194,922
S-HNI (Min) 14 476 ₹209,916
S-HNI (Max) 66 2,244 ₹989,604
B-HNI (Min) 67 2,278 ₹1,004,598
Lot Size Calculator

Suraksha Diagnostic IPO Promoter Holding

The promoters of the company are Dr. Somnath Chatterjee, Ritu Mittal and Satish Kumar Verma.

Share Holding Pre Issue 61.07%
Share Holding Post Issue  

About Suraksha Diagnostic Limited

Incorporated in 2005, Suraksha Diagnostic Limited offers pathology, radiology testing and medical consultancy services. The company has a central reference laboratory with 8 satellite laboratories and 215 customer touchpoints, including 49 diagnostic centres and 166 sample collection centres as of June 30, 2024, across West Bengal, Bihar, Assam, and Meghalaya.

The company offers its customers online and offline medical consultation services under one roof via 44 diagnostic centres, which house 120 polyclinics with more than 750 doctors.

The operation of the diagnostic centres is supported by the technology platforms and systems that the company uses to streamline, such as its Laboratory Information Management System (“LIMS”), its fully integrated Radiology Information System (“RIS”), its Picture Archive Communication System (“PACS”) and its Enterprise Resource Planning System (“ERP”).

The company offers vaccination services and customized testing packages for disease prediction/early detection. The company uses digital pathology and artificial intelligence to generate blood tests. All radiology reporting is done through a digital platform that allows cases to be reported from all diagnostic centres, significantly reducing turnaround time.

Competitive Strengths are:

  1. Well-positioned diagnostics chain to capture the large growth opportunities for organized diagnostics chains in the fragmented markets for diagnostic services in eastern and northeastern India.
  2. Integrated diagnostics provider offering pathology and radiology testing and medical consultancy services from a single source.
  3. Well-invested and technologically advanced clinical infrastructure.
  4. Commitment to quality driving high individual consumer business share and customer retention.
  5. Management team with relevant industry experience.

 

Suraksha Diagnostic Limited Financial Information (Restated Consolidated)

Suraksha Diagnostic Limited’s revenue increased by 14.75% and profit after tax (PAT) rose by 281.32% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended 30 Jun 2024 31 Mar 2024 31 Mar 2023 31 Mar 2022
Assets 314.20 300.21 281.20 275.96
Revenue 61.85 222.26 193.69 225.77
Profit After Tax 7.67 23.13 6.07 20.82
Net Worth 187.05 179.41 155.93 145.84
Reserves and Surplus 176.80 170.88 147.40 137.31
Total Borrowing 7.57 8.64 14.01 19.03
Amount in ₹ Crore

Key Performance Indicator

KPI as of March 31, 2024.

KPI Values
ROE 14.09%
ROCE 21.46%
Debt/Equity 0.2
RoNW 14.09%
P/BV 13.1
PAT Margin (%) 10.57

Check Suraksha Diagnostic IPO Peer Comparison here.

  Pre IPO Post IPO
EPS (Rs)  4.44  
P/E (x)  99.31  

Note:

  • The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
  • The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of June 30, 2024 that is available in RHP.

Objects of the Issue (Suraksha Diagnostic IPO Objectives)

The Company will not receive any proceeds from the Offer for sale and all proceeds will go to the Selling Shareholders.

Suraksha Diagnostic IPO Review (May apply)

[Dilip Davda]  The company is a one-stop pathology and radiology testing, and medical consultation services solution provider having East region centric play. It enjoys market share of around 1.26% in the area of its operation and that is scaling up with its new centre opening, which adds to its top line and over the period start contributing to its bottom line. It suffered a minor setback for FY23 due to non-contribution of such centres opened in FY22 and their related expenses. However, the company is back on track as indicated by FY24 performance and is poised for bright prospects with its expansion plans afoot. Based on FY25 annualized earnings, the issue appears fully priced discounting all near term positives. However, well-informed investors may park funds for long term. Read detail review…


Sorry, we couldn’t find the subscription details. Note that the bidding starts at 10 AM and ends at 5 PM on the days when the public issue is open.

Suraksha Diagnostic IPO Prospectus

 

Suraksha Diagnostic Limited Contact Details

Suraksha Diagnostic Limited
Plot No. DG-12/1
Action Area 1D, Premises No. 02-0327
New Town, Rajarhat Kolkata 700 156
Phone: 91 33 66059750
Email: investors@surakshanet.com
Websitehttps://www.surakshanet.com/

Suraksha Diagnostic IPO Registrar

Kfin Technologies Limited

Phone: 04067162222, 04079611000
Email: sdl.ipo@kfintech.com
Websitehttps://kosmic.kfintech.com/ipostatus/